» Articles » PMID: 35846029

Single Cell Proteogenomic Sequencing Identifies a Relapse-fated AML Subclone Carrying -ITD with CN-LOH at Chr13q

Overview
Journal EJHaem
Specialty Hematology
Date 2022 Jul 18
PMID 35846029
Authors
Affiliations
Soon will be listed here.
Abstract

Internal tandem duplication of the Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 (-ITD) is one of the most clinically relevant mutations in acute myeloid leukemia (AML), with a high -ITD allelic ratio (AR) (≥0.5) being strongly associated with poor prognosis. -ITDs are heterogeneous, varying in size and location, with some patients having multiple -ITDs. Bulk cell-based approaches are limited in their ability to reveal the clonal structure in such cases. Using single-cell proteogenomic sequencing (ScPGseq), we attempted to identify a relapse-fated subclone in an AML case with mutations in , , and tyrosine kinase domain and two -ITDs (21 bp and 39 bp) (low AR) at presentation, then relapsed only with and mutations and one -ITD (high AR). This relapse-fated subclone at presentation (∼2.1% of sequenced cells) was characterized by the presence of a homozygous 21 bp -ITD resulting from copy neutral loss of heterozygosity (CN-LOH) of chr13q and an aberrant, immature myeloid cell surface signature, contrast to the cell surface phenotype at presentation. In contrast to results from multicolor flow-cytometry, ScPGseq not only enabled the early detection of rare relapse-fated subclone showing immature myeloid signature but also highlighted the presence of homozygous 21 bp -ITDs in the clone at presentation.

Citing Articles

Single cell proteogenomic sequencing identifies a relapse-fated AML subclone carrying -ITD with CN-LOH at chr13q.

Kim T, Lee H, Capo-Chichi J, Chang M, Yoo Y, Basi G EJHaem. 2022; 3(2):426-433.

PMID: 35846029 PMC: 9175792. DOI: 10.1002/jha2.390.

References
1.
Demaree B, Delley C, Vasudevan H, Peretz C, Ruff D, Smith C . Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. Nat Commun. 2021; 12(1):1583. PMC: 7952600. DOI: 10.1038/s41467-021-21810-3. View

2.
Bland J, Altman D . Multiple significance tests: the Bonferroni method. BMJ. 1995; 310(6973):170. PMC: 2548561. DOI: 10.1136/bmj.310.6973.170. View

3.
Wu J, Xiao Y, Sun J, Sun H, Chen H, Zhu Y . A single-cell survey of cellular hierarchy in acute myeloid leukemia. J Hematol Oncol. 2020; 13(1):128. PMC: 7517826. DOI: 10.1186/s13045-020-00941-y. View

4.
Soare D, Radu E, Dumitru I, Popov V, Bumbea H, Vladareanu A . FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression. J Cell Mol Med. 2020; 24(13):7675-7679. PMC: 7339186. DOI: 10.1111/jcmm.15255. View

5.
Patel J, Gonen M, Figueroa M, Fernandez H, Sun Z, Racevskis J . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89. PMC: 3545649. DOI: 10.1056/NEJMoa1112304. View